The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Variant allele frequency in patients with SF3B1-mutated MDS
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, presents research investigating the significance of variant allele frequency (VAF) in patients with SF3B1-mutated myelodysplastic neoplasms (MDS). Patients with SF3B1 VAF of lower than 10% exhibited more adverse disease biology and increased co-mutation frequency compared to those with VAF of ≥ 10%, indicating SF3B1 mutations as the primary genomic driver in high VAF cases, while likely sub-clonal in low VAF cases. Despite this distinction, there were no significant differences in leukemia-free survival (LFS) and overall survival (OS) between the two cohorts. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Rigel, AbbVie, Servier, COTA Healthcare.
